The United Kingdom and Denmark have decided to inject BioNTech vaccines against Kovid for 12 and 6 weeks respectively. While the manufacturer provides for a period of 21 days, he warns about the lack of data guaranteeing maximum effectiveness under these conditions.
The BioNTech laboratory warned on Tuesday that the maximum effectiveness of its vaccine against Kovid-19 has not been demonstrated if a second injection is delayed, a strategy implemented by many countries to vaccinate many people or Has been considered.
“The vaccine’s efficacy and safety have not been evaluated for other dosing programs”, explained the German company, which developed with it, American Pfizer in the United States and, compared to two injections 21 days apart applied during clinical trials. It is the first vaccine authorized in the European Union.
Facing limited stock of this product, Denmark on Monday announced two doses to be kept for six weeks; The UK, which authorized the vaccine before the European Union in early December, allows up to 12 weeks between the two injections.
Vaccinate more people now
“In this way we will now be able to vaccinate more people,” Soren Brostrom, head of the Danish National Health Agency interviewed by public television TV2, reported that the analysis was based on the documentation presented. Laboratories reported a second dose received “between 19 and 42 days” after the first.
In Germany, the Ministry of Health has asked health officials to assess options for extending the deadline, according to a document consulted by the AFP on Monday.
A spokesperson said, “Although the data suggests that there is partial protection even after 12 days of the first dose, there is no data that suggests the protection is beyond 21 days.” By biotech.
“We believe a second injection is necessary to provide maximum protection against the disease,” adds the Mainz-based company specializing in messenger RNA. However, “decisions on alternative dosage regimens are made by national health officials” with which the laboratory is in “constant dialogue”.
There is also concern about the decisions of the Modern vaccine in Denmark, which are currently being approved by AstraZeneca in the European Union and the British case.
